Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The company's drug candidate, Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is currently in a Phase 3 study for the treatment of Niemann-Pick Disease Type C, a rare and fatal genetic disease. More information can be found at clinicaltrials.gov under study ID NCT04860960. Additional indications for the active ingredient in Trappsol® Cyclo™, are in development such as Alzheimer's disease, NCT05607615.